Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.35 |
| ▸ | MGLL | Q99685 | 3/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1028207 | 1.00 | PTGS1 (0.35) | PTGS1PTGS2MGLLFAAHNFKB1 | |
| SCHEMBL1028209 | 1.00 | PTGS1 (0.35) | PTGS1PTGS2MGLLFAAHNFKB1 | |
| SCHEMBL1027701 | 1.00 | PTGS1 (0.35) | PTGS1PTGS2MGLLFAAHNFKB1 | |
| SCHEMBL1027172 | 0.87 | MGLL (0.31) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL1027431 | 0.87 | MGLL (0.31) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL1027170 | 0.87 | MGLL (0.31) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL1027429 | 0.87 | MGLL (0.31) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL1026489 | 0.81 | PTGS1 (0.35) | PTGS1PTGS2MGLLFAAHNFKB1 | |
| SCHEMBL1029959 | 0.81 | PTGS1 (0.35) | PTGS1PTGS2MGLLFAAHNFKB1 | |
| SCHEMBL1026490 | 0.81 | PTGS1 (0.35) | PTGS1PTGS2MGLLFAAHNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1479669-B1 | Optically active maleimide derivatives and polymaleimides for use as chiral adsorbent in chromatography | TOSOH CORP (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-7645889-B2 | Optically active polymaleimide derivatives and process for their production | TOSOH CORPORATION (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20080230482-A1 | Optically active polymaleimide derivatives and process for their production | TOSOH CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| US-7381742-B2 | Optically active polymaleimide derivatives and process for their production | TOSOH CORPORATION (JP) | 2008-06-03 | — | — | US | disclosed |
| US-20070131616-A1 | Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them | TOSOH CORPORATION (JP) | 2007-06-14 | — | — | US | disclosed |
| US-7186750-B2 | Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them | TOSOH CORPORATION (JP) | 2007-03-06 | — | — | US | disclosed |
| US-20040235937-A1 | Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them | TOSOH CORPORATION (JP) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080230482-A1 | Optically active polymaleimide derivatives and process for their production | CYBA, COASY, MEP1B | PTGS1 1062/4885PTGS2 998/4885MGLL 2036/4885 |
| US-20040235937-A1 | Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them | MACF1, MEP1B, CYBA | PTGS1 860/4885PTGS2 852/4885MGLL 2056/4885 |
| US-20070131616-A1 | Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them | MACF1, MEP1B, ACMSD | PTGS1 1162/4885PTGS2 861/4885MGLL 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.